Zobrazeno 1 - 6 of 6 pro vyhledávání: '"Marie Toukam"'
1
Akademický článek
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)
Autor: Heinz Wiendl, John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary R. Cutter, Gavin Giovannoni, Joep Killestein, Rose Domingo-Horne, Marie Toukam, Aimie Nunn, Amir-Hadi Maghzi, Robert Kuhelj, Tyler Lasky
Publikováno v: Neurology and Therapy, Vol 13, Iss 5, Pp 1385-1401 (2024)
Abstract Introduction Following NOVA (part 1) and the approval of the subcutaneous (SC) route of administration of natalizumab by the European Medicines Agency, an extension phase of the NOVA phase IIIb study (part 2) was initiated to collect patient
Externí odkaz: https://doaj.org/article/b321bac547dd4d7899d298075a610cb1
Zobrazit plný text záznamu
5
Abstract 4151: Effect of camidanlumab tesirine (Cami) as monotherapy and in combination with pembrolizumab (PEM) on the immune cell profile in patients with selected advanced solid tumors
Autor: Igor Puzanov, Christopher T. Chen, Patricia LoRusso, Kyriakos P. Papadopoulos, Shivaani Kummar, Erika Hamilton, Yvan LeBruchec, Karin Havenith, Serafino Pantano, Marie Toukam, Jens Wuerthner, Joseph Boni
Publikováno v: Cancer Research. 82:4151-4151
Background: Cami, an investigational anti-CD25, pyrrolobenzodiazepine-based antibody drug conjugate, imparts cytotoxicity on CD25+ regulatory T cells (Tregs), leading to immunomodulatory effects (eg, modifying effector T cell [Teff]:Treg intratumoral
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e8a1d7dcb51a664dc0ccd411b5731fc
https://doi.org/10.1158/1538-7445.am2022-4151
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje